QUESTION10 Jun 2019 12:43
Hi Thoth and all. Hope all keeping ok. If we go through phase 3 with chk1 and get fast tracked for ovarian cancer, am I right in thinking you say that alone is 20p-40p share price? Also, look like data from small lung cancer studies looks amazing in triple therapy...if that was successful in humans, how much could that add to share price? That is without tyk2 getting any value?
All views appreciated